Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2021 07:28 ET | Source: Research and Markets

Worldwide Nanobiotechnology Industry to 2029 - Featuring Aduro BioTech, Calando Pharmaceuticals and Baxter International Among Others

Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Nanobiotechnology Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
February 05, 2019 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference

FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
December 20, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019

FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
December 17, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel

FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
December 06, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event

FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
December 04, 2018 07:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court

FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...